243 related articles for article (PubMed ID: 36782152)
21. Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study.
Paulson S; Ray D; Aranha S; Scales A; Wang Y; Liu E
Oncol Ther; 2022 Dec; 10(2):463-479. PubMed ID: 36136274
[TBL] [Abstract][Full Text] [Related]
22. Real-world comparison of healthcare resource utilization and costs of [
Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
[TBL] [Abstract][Full Text] [Related]
23. GEP-NET radiomics: a systematic review and radiomics quality score assessment.
Staal FCR; Aalbersberg EA; van der Velden D; Wilthagen EA; Tesselaar MET; Beets-Tan RGH; Maas M
Eur Radiol; 2022 Oct; 32(10):7278-7294. PubMed ID: 35882634
[TBL] [Abstract][Full Text] [Related]
24. Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.
Harrow B; Fagnani F; Nevoret C; Truong-Thanh XM; de Zélicourt M; de Mestier L
Adv Ther; 2022 Apr; 39(4):1754-1771. PubMed ID: 35190997
[TBL] [Abstract][Full Text] [Related]
25. Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors.
Altieri B; Barrea L; Modica R; Bottiglieri F; de Cicco F; Muscogiuri G; Circelli L; Savarese G; Di Somma C; Savastano S; Colao A; Faggiano A
Endocrine; 2022 Feb; 75(2):623-634. PubMed ID: 34533768
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological Characteristics of Gastroenteropancreatic Neuroendocrine Tumors: 10 Years of Experience From a Single Center.
Şentürk M; Acar B; Yildirim MA; Çakir M; Küçükkartallar T; Vatansev C
Pancreas; 2022 Feb; 51(2):159-163. PubMed ID: 35404891
[TBL] [Abstract][Full Text] [Related]
27. Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors.
Barrea L; Muscogiuri G; Modica R; Altieri B; Pugliese G; Minotta R; Faggiano A; Colao A; Savastano S
Front Endocrinol (Lausanne); 2021; 12():649496. PubMed ID: 33815296
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological and survival features of neuroendocrine tumors: A retrospective analysis of 153 cases, our current remarks on a heterogeneous tumor group, and still unmet future expectations.
Kahraman S; Bardakci M; Aykan MB; Yasar S; Erol C; Hizal M; Akinci MB; Kos FT; Kos T; Dede DS; Karadurmus N; Yalcin S; N Sendur MA; Yalcin B
J Cancer Res Ther; 2023; 19(2):347-354. PubMed ID: 37006071
[TBL] [Abstract][Full Text] [Related]
29. Consideration of quality of life in the treatment decision-making for patients with advanced gastroenteropancreatic neuroendocrine tumors.
Naraev BG; Mailman J; Halfdanarson TR; Soares HP; Mittra ES; Hallet J
Expert Rev Anticancer Ther; 2023 Jun; 23(6):601-615. PubMed ID: 37158050
[TBL] [Abstract][Full Text] [Related]
30. Gastroenteropancreatic Neuroendocrine Tumors.
Cives M; Strosberg JR
CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
[TBL] [Abstract][Full Text] [Related]
31. Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework.
de Hosson LD; van Veenendaal LM; Schuller Y; Zandee WT; de Herder WW; Tesselaar MET; Klümpen HJ; Walenkamp AME
Ann Oncol; 2017 Dec; 28(12):3022-3027. PubMed ID: 29045525
[TBL] [Abstract][Full Text] [Related]
32. Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant
Parghane RV; Bhandare M; Chaudhari V; Ostwal V; Ramaswamy A; Talole S; Shrikhande SV; Basu S
J Nucl Med; 2021 Nov; 62(11):1558-1563. PubMed ID: 33637590
[TBL] [Abstract][Full Text] [Related]
33. Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness.
Barrea L; Altieri B; Muscogiuri G; Laudisio D; Annunziata G; Colao A; Faggiano A; Savastano S
Nutrients; 2018 Dec; 10(12):. PubMed ID: 30513732
[TBL] [Abstract][Full Text] [Related]
34. Long-term Outcomes of Gastroenteropancreatic Neuroendocrine Tumors.
Chi W; Warner RRP; Chan DL; Singh S; Segelov E; Strosberg J; Wisnivesky J; Kim MK
Pancreas; 2018 Mar; 47(3):321-325. PubMed ID: 29401168
[TBL] [Abstract][Full Text] [Related]
35. Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis.
Laffi A; Spada F; Bagnardi V; Frassoni S; Pisa E; Rubino M; Barberis M; Fazio N
J Endocrinol Invest; 2022 Feb; 45(2):317-325. PubMed ID: 34282554
[TBL] [Abstract][Full Text] [Related]
36. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
[TBL] [Abstract][Full Text] [Related]
37. Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors.
Diamantopoulos LN; Laskaratos FM; Kalligeros M; Shah R; Navalkissoor S; Gnanasegaran G; Banks J; Smith J; Jacobs B; Galanopoulos M; Mandair D; Caplin M; Toumpanakis C
Neuroendocrinology; 2021; 111(7):650-659. PubMed ID: 32541155
[TBL] [Abstract][Full Text] [Related]
38. Virtual Care for Patients with Advanced Well Differentiated Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET).
Phillips WJ; Pradier M; Goodwin R; Vickers M; Asmis T
Curr Oncol; 2024 Feb; 31(2):952-961. PubMed ID: 38392065
[TBL] [Abstract][Full Text] [Related]
39. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
[TBL] [Abstract][Full Text] [Related]
40. Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?
Das S; Dasari A
Curr Oncol Rep; 2021 Mar; 23(4):43. PubMed ID: 33719003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
